
What smart money is saying about Axogen
1 fund in our archive has pitched Axogen, most recently Brown Capital Small Company Fund in September 2025.
AxoGen, Inc., together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and Avive Soft Tissue Membrane, a processed human umbilical cord membrane that can be used as a resorbable soft tissue covering to separate tissues in the surgical bed. In addition, the company offers AxoTouch two point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. It provides its products to hospitals, surgery centers, and military hospitals plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons in the United States, Canada, Germany, the United Kingdom and other European countries, South Korea, and internationally. AxoGen, Inc. is headquartered in Alachua, Florida.
Get an email when a fund buys, sells or pitches it
Position history
Every position in Axogen on record in the archive was reported in Q3 2025, across 1 fund letter, with 1 buy (opened or added).
| Quarter | Letters | Bought | Sold | Theses |
|---|---|---|---|---|
| Q3 2025 | 1 | 1 | 0 | 1 |
Bought and Sold count moves: the same sentence published by several funds of one house in a quarter counts once.
Fund activity · 1 position · 1 move
- New positionBrown Capital Small Company FundSeptember 2025
“Additions and Deletions We added four new companies—Axogen (AXGN), Corcept Therapeutics (CORT), Intapp (INTA) and Mama’s Creations (MAMA)—to the portfolio this quarter.”
Axogen
Fund coverage · 1 thesis
- Brown Capital Small Company FundSeptember 2025
Axogen offers the only approved human nerve graft with strong clinical evidence, high growth, and upcoming BLA exclusivity driving profitability.
Read the full thesis
Read every full thesis on Axogen
Read all 1 thesis in full, with each fund's reasoning, and get unlimited access to the archive.
View plans→